Cold Genesys, Inc. Continuing Development of CG0070 Oncolytic Virus With GMCSF Expression

September 07, 2012 -- Cold Genesys, Inc. has reactivated an IND and is pursuing a special protocol assessment (SPA) with the FDA on a pivotal integrated phase II/III clinical trial for patients with Non-Muscle Invasive Bladder Cancer (NMIBC) who have previously failed BCG. Result of SPA decision will be announced in the week of September 10th 2012.

Those interested in the development of this innovative therapy please contact the company 949.200.7680.